Published in Cancer Immunol Res on June 07, 2016
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267
Phase II, 2nd Line Melanoma - RAND Monotherapy | NCT00612664
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat Immunol (2006) 3.20
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52
Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 2.40
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev (2009) 2.34
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol (2002) 2.05
In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol (2002) 1.70
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med (1998) 1.54
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol (2003) 1.54
MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol (2008) 1.45
The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol (2004) 1.40
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol (2004) 1.28
Costimulation of CD8 T cell responses by OX40. J Immunol (2004) 1.24
ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol (2008) 1.23
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J (2008) 1.19
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev (2011) 1.17
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol (2008) 1.09
Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) (2008) 1.09
When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood (2010) 1.08
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunol Rev (2013) 0.97
Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity. Eur J Immunol (2011) 0.95
Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett (2012) 0.86
Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant. Mol Cells (2011) 0.85
Unified immune modulation by 4-1BB triggering leads to diverse effects on disease progression in vivo. Cytokine (2011) 0.78